Современные тенденции лечения пациентов с мочекаменной болезнью, осложненной хроническим калькулезным пиелонефритом
##plugins.themes.bootstrap3.article.main##
Abstract
Urolithiasis as a chronic pathological process having a ubiquitous, coupled with the need for emergency medical care, often resulting in permanent disability, not to lose over the years its importance and relevance. This calculous pyelonephritis is a leading pathology among the diseases of the urinary system, accompanied by disturbances of urodynamics and changes in renal parenchyma. In connection with the above stated it seems urgent comprehensive comparative approach to the study of metabolic disturbances in patients with urolithiasis in order to identify possible causes Lithogenesis and its complications, including pyelonephritis, for further development of optimal schemes of urolithiasis treatment and prevention of stone formation in these patients.
The objective: to evaluate litholytic and anti"inflammatory efficacy of Flavia® drug in patients with chronic calculous pyelonephritis. Patients and methods. The study involved 115 patients (74 men and 41 women aged from 23 to 76 years) who had been diagnosed with a stone in cup size from 5 to 10 mm, followed by chronic calculous pyelonephritis in a phase of latent inflammation. 60 patients who took Flavia® 1 caps. 2 times a day for 3 months. the main group (OG), 55 patients with the comparison group (HS) took herbal diuretics.
Results. The results show that particularly relevant is the use of Flavia ® in patients with chronic calculous pyelonephritis, as the drug helps rid the patients of stones and relief of the inflammatory process, which in turn reduces the likelihood of recurrence of stone formation.
Conclusion. The use of the drug has a pronounced Flavia® litholytic and litokinetichesky effect, as evidenced by not only the self-discharge of stones from the exhaust of patients, as well as significant reduction in the size of stones trapped in the cups. Anti-inflammatory and anti-microbial effectiveness Flavia® due to synergistic action of its active ingredients provides clinical efficacy in 96.7% of patients, thus expanding the scope of conservative treatment of urolithiasis complicated by chronic calculous pyelonephritis.
##plugins.themes.bootstrap3.article.details##
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Досвід трансуретрального ендоскопічного лазерного лікування сечокамʼяної хвороби та використання препарату Flavia / Джуран Б.В., Когут В.В., Бойко А.І., Крижевський В.В. [та ін.] // Здоровье мужчины. – 2011. – No 1. – С. 96–98.
Россіхін В.В. Ефективність фітопрепарату Flavia у післяопераційному лікуванні хворих нефролітіазом, які перенесли дистанційну ударно-хвильову літотрипсію / Россіхін В.В., Хощенко Ю.А., Осіпов П.Г. // Здоровье мужчины. – 2010. – No 4. – С. 44–46.
Инструкция по применению препарата «FlavіaTM» в стране-производителе (Swiss Caps AG, Switzerland).
Тиктинский О.Л., Александров В.П. Мочекаменная болезнь. – СПб: Питер. 2000. – 379 с.
A prospective, randomized, controlled study to evaluate the efficacy and tolerability of Ayurvedic formulation «varuna and banana stem» in the management of urinary stones / Patankar S., Dobhada S., Bhansali M. [et al.] // J Altern Complement Med. – 2008. – No 14 (10). – Р. 1287–90.
Densted J, Khоury S. Stone disease / 2nd International Consultation on stone disease. – 2008.
Mawatari K., Mashiko S., Watanabe M., and Nakagomi K. Fluorometric determination of khellin in human urine and serum by high-performance liquid chromatography using postcolumn photoirradiation, Analytical Sciences. 19:1071–1073 (2003).
Kursinszki L., Troilina J., and Szoke E. HPLC-determination of visnagin in genetically transformed root cultures of Ammi visnaga growing in liquid medium, Chemia Analityczna. 45:229–236 (2000).
Gunaydin K. and Erim F.B. Determination of khellin and visnagin in Ammi visnaga fruits by capillary electrophoresis, Journal of Chromatography A. 954:291–294 (2002).
Singh S.S. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs, Current Drug Metabolism. 7:165–182 (2006).
Khan Z.A., Assiri A.M., Al-Afghani H.M., and Maghrabi T.M. Inhibition of oxalate nephrolithiasis with Ammi visnaga (AI(Khillah), Int Urol Nephrol. 33:605–608 (2001).
Guidelines on Urolithiasis C. Türk, T. Knoll, A. Petrik, K. Sarica, A. Skolarikos, M. Straub, C. Seitz.35:98–100 (2014).